DJIA 16,987.51 -61.49 -0.36%
NASDAQ 4,567.60 -24.21 -0.53%
S&P 500 1,985.54 -11.91 -0.60%
market minute promo

Eli Lilly & Co. (NYSE: LLY)

65.27 0.09 (0.14%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

LLY $65.27 0.14%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $65.25
Previous Close $65.18
Daily Range $65.00 - $65.54
52-Week Range $47.53 - $65.70
Market Cap $72.9B
P/E Ratio 20.69
Dividend (Yield) $1.96 (3.0%)
Ex-Dividend Date
Dividend Pay Date
08/13/14
09/10/14
Volume 5,376,806
Average Daily Volume 3,517,779
Current FY EPS $2.79

Sector

Healthcare

Industry

Drugs

Eli Lilly & Co. (LLY) Description

The Company discovers, develops, manufactures and sells products in one of its business segment of pharmaceutical products to prevent and treat human diseases. Website: http://www.lilly.com/

News & Commentary

These 7 States Have the Highest Rates of Pancreatic Cancer

Pancreatic cancer is arguably the most lethal form of the disease. Find out which seven states this disease occurs in most often, as well as what new pathways are being tested to treat this terrible disease.

New Diabetes Drugs Gain Approval - Florins Versus Oral Insulin

UPDATE 1-Lilly stomach cancer drug prolongs life in colon cancer study

Lilly colon cancer drug succeeds in late stage study

Lilly Announces CYRAMZA Phase III Second-Line Colorectal Cancer Trial Meets Primary Endpoint Of Over

Lilly Announces CYRAMZA Phase III Second-Line Colorectal Cancer Trial Meets Primary Endpoint Of Overall Survival

Eli Lilly/Boehringer's Insulin Biosimilar Gains EU Approval - Analyst Blog

After Apple: Tech's Takeover of Healthcare Officially Begins

Ebola is spreading, new diabetes and obesity drugs, and Apple and Google move into healthcare, because this is where the money is.

Glaxo (GSK) Updates on Asthma Candidate Mepolizumab - Analyst Blog

Glaxo (GSK) Updates on Asthma Candidate Mepolizumab - Analyst Blog

3 Reasons MannKind Corporation's Stock Could Fall

MannKind is dependent on the launch of inhaled insulin Afrezza and its marketing partner Sanofi.

Preview: FDA September 17 Adcom On Testosterone Replacement Therapy

See More LLY News...

LLY's Top Competitors

LLY $65.27 (0.14%)
Current stock: LLY
JNJ $104.58 (0.03%)
Current stock: JNJ
PFE $29.43 (-0.67%)
Current stock: PFE
RHHBY $36.70 (-0.54%)
Current stock: RHHBY